Ryoncil® Data Supports Earlier Use, Pivotal Adult Trial for SR-aGvHD Planned
MESO sits 88% above its 52-week low of $9.61.
Summary
New clinical data for Ryoncil® highlights the importance of early treatment and supports a planned pivotal trial for adult SR-aGvHD, potentially tripling the addressable market.
Key Events · Product Development and Regulatory · MESO
-
New Clinical Data Presented
Mesoblast presented data at the February 2026 Tandem Meetings showing high survival rates for Ryoncil® in SR-aGvHD across both pediatric and adult patients, regardless of treatment line or ruxolitinib resistance.
-
Emphasis on Early Treatment
The data highlighted that 15% of patients receiving Ryoncil® as ≥ third-line treatment died before completing a full course, compared to only 2% in the Phase 3 trial (second-line), underscoring the importance of early intervention.
-
Pivotal Adult Trial Planned
Favorable survival outcomes in adult patients under the EIND program provide strong rationale for a planned pivotal trial for early use of Ryoncil® in adults with severe SR-aGvHD, with enrollment expected to begin this quarter.
-
Significant Market Expansion Potential
A successful adult trial could lead to a label extension for Ryoncil® in adults, a population estimated to be three times larger than the current pediatric SR-aGvHD market.
Analysis · MESO · Life Sciences
Mesoblast presented new data at the Tandem Meetings demonstrating high survival rates for Ryoncil® in steroid-refractory acute graft-versus-host disease (SR-aGvHD) in both children and adults. The findings emphasize the critical importance of early treatment initiation to maximize patient survival. Crucially, the favorable outcomes in adult patients under the Emergency Investigational New Drug (EIND) program provide strong support for a planned pivotal trial for Ryoncil® in adults with severe SR-aGvHD, expected to commence enrollment this quarter. A successful trial could lead to a significant label extension, targeting a patient population approximately three times larger than the current pediatric indication, representing a substantial growth opportunity for the company.
At the time of this filing, MESO was trading at $18.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $9.61 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.